Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 3.443
Filtrar
1.
Narra J ; 4(2): e826, 2024 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-39280310

RESUMEN

Parkinson's disease (PD) manifests as a movement and brain function disorder characterized by symptoms such as resting tremors, rigidity, bradykinesia, and postural instability, leading to disability among patients. The use of psychostimulants such as caffeine has been associated with the improvement of motor symptoms in PD patients; however, studies regarding the effect of caffeine adjuvant therapy on motor function among PD patients in the Indonesian population are lacking. The aim of this study was to evaluate motor improvement as measured by the change in scores of the Movement Disorder Society - Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III) among PD patients receiving caffeine adjuvant. A double-blind randomized controlled trial (RCT) was conducted among PD patients at Dr. Soetomo General Academic Hospital and Universitas Airlangga Hospital, Surabaya, Indonesia, from April to August 2023. A total of 27 patients were enrolled and randomly assigned to an intervention (receiving caffeine adjuvant, n=15) and control group (receiving placebo, n=12). Motor improvement was measured using the UPDRS III score prior to intervention and three weeks after. The Chi-squared test was used to analyze the difference in UPDRS III scores between the two groups. Motor improvement, as demonstrated by a reduction in the UPDRS III score, was observed in patients receiving caffeine adjuvant compared to those receiving placebo (80.0% vs 16.7%; p=0.004). Regarding the safety profile, only four out of 15 (26.6%) patients treated with caffeine reported minor adverse events. These conditions improved over time during the intervention. None of the 12 patients in the placebo reported adverse events. This study provides valuable insights into the initial dosage of caffeine that improves motor function in PD patients with minimum adverse effects.


Asunto(s)
Cafeína , Enfermedad de Parkinson , Humanos , Cafeína/uso terapéutico , Cafeína/administración & dosificación , Cafeína/farmacología , Cafeína/efectos adversos , Enfermedad de Parkinson/tratamiento farmacológico , Método Doble Ciego , Masculino , Femenino , Indonesia , Persona de Mediana Edad , Anciano , Resultado del Tratamiento , Estimulantes del Sistema Nervioso Central/uso terapéutico , Estimulantes del Sistema Nervioso Central/administración & dosificación , Estimulantes del Sistema Nervioso Central/efectos adversos
2.
Nutrients ; 16(17)2024 Aug 31.
Artículo en Inglés | MEDLINE | ID: mdl-39275223

RESUMEN

Although theanine in matcha improves sleep quality and cognitive function, the caffeine in green tea is thought to worsen sleep quality. Therefore, this study investigated the factors behind the observed improvements in subjective sleep quality in matcha. A placebo-controlled randomized double-blind parallel-group study was conducted on healthy Japanese men and women aged 27-64 years. After 4 weeks of consuming 2.7 g of matcha daily (containing 50.3 mg theanine, 301.4 mg catechins, and 71.5 mg caffeine), no significant differences were observed between the control and matcha groups on total sleep time, sleep latency, wake after sleep onset, or sleep efficiency measured by electroencephalography (EEG). However, the sleep questionnaire Oguri-Shirakawa-Azumi Sleep Inventory, the Middle-age and Aged version (OSA-MA), administered immediately after waking showed a trend toward increased satisfaction with sleep time (p < 0.1), and EEG measurements indicated significantly shortened wake-up times after waking with matcha intake (p < 0.05). The Beck Depression Inventory-II scores also tended to decrease (p < 0.1). The continuous intake of matcha may offer improved subjective sleep quality and emotional stability despite not offering significant changes in objective sleep parameters.


Asunto(s)
Electroencefalografía , Sueño , Humanos , Masculino , Femenino , Adulto , Método Doble Ciego , Persona de Mediana Edad , Sueño/fisiología , Cafeína/administración & dosificación , Cafeína/farmacología , , Calidad del Sueño , Salud Mental , Glutamatos/administración & dosificación , Encuestas y Cuestionarios
3.
Invest Ophthalmol Vis Sci ; 65(11): 10, 2024 Sep 03.
Artículo en Inglés | MEDLINE | ID: mdl-39230997

RESUMEN

Purpose: To determine the acute effect of caffeine intake on the retinal responses as measured with a global-flash multifocal electroretinogram (gfmERG) protocol at different contrast levels. Methods: Twenty-four young adults (age = 23.3 ± 2.4 years) participated in this placebo-controlled, double-masked, balanced crossover study. On two different days, participants orally ingested caffeine (300 mg) or placebo, and retinal responses were recorded 90 minutes later using a gfmERG at three contrast levels (95%, 50%, and 29%). The amplitude response density and peak time of the direct and induced components (direct component [DC] and induced component [IC], respectively) were extracted for five different eccentricities (1.3°, 5.0°, 9.6°, 15.2°, and 21.9°). Axial length, spherical equivalent refraction, habitual caffeine intake, and body weight were considered as continuous covariates. Results: Increased IC amplitude response density was found after caffeine ingestion in comparison to placebo (P = 0.021, ƞp2 = 0.23), specifically for the 95% and 50% stimulus contrasts (P = 0.024 and 0.018, respectively). This effect of caffeine on IC amplitude response density was independent of the retinal eccentricity (P = 0.556). Caffeine had no effect on DC amplitude response density or DC and IC peak times. Conclusions: Our results show that oral caffeine intake increases the inner electro-retinal activity in young adults when viewing stimuli of high- (95%) to medium-contrast (50%). Given the increasing evidence that the inner retinal function is involved in the emmetropization process, these results may suggest that caffeine or its derivatives could potentially play a role in the mechanisms involved in eye growth.


Asunto(s)
Cafeína , Estudios Cruzados , Electrorretinografía , Humanos , Cafeína/administración & dosificación , Método Doble Ciego , Masculino , Adulto Joven , Femenino , Electrorretinografía/efectos de los fármacos , Administración Oral , Adulto , Retina/efectos de los fármacos , Retina/fisiología , Estimulantes del Sistema Nervioso Central/administración & dosificación , Estimulantes del Sistema Nervioso Central/farmacología , Estimulación Luminosa , Sensibilidad de Contraste/fisiología , Sensibilidad de Contraste/efectos de los fármacos
4.
J Int Soc Sports Nutr ; 21(1): 2400513, 2024 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-39246027

RESUMEN

BACKGROUND: Caffeine is one of the most popular ergogenic aids consumed by athletes. Caffeine's ergogenic effect has been generally explained by its ability to bind to adenosine receptors, thus modulating pain and reducing perceived exertion. Another pharmacological agent that may improve performance due to its analgesic proprieties is paracetamol. This study aimed to explore the effects of caffeine, paracetamol, and caffeine + paracetamol consumption on muscular endurance, strength, power, anaerobic endurance, and jumping performance. METHODS: In this randomized, crossover, double-blind study, 29 resistance-trained participants (11 men and 18 women) ingested either a placebo, caffeine (3 mg/kg), paracetamol (1500 mg) or caffeine + paracetamol 45 min before the testing sessions. The testing sessions included performing the bench press exercise with 75% of one-repetition maximum to momentary muscular failure, isokinetic knee extension and flexion at angular velocities of 60°/sec and 180°/sec, Wingate, and countermovement jump (CMJ) tests. RESULTS: Compared to placebo, isolated caffeine ingestion increased the number of repetitions performed in the bench press (p = 0.005; d = 0.42). Compared to placebo, isolated caffeine ingestion and/or caffeine + paracetamol consumption was ergogenic for strength (torque), muscular endurance (total work), or power in the isokinetic assessment, particularly at slower angular velocities (p = 0.027 to 0.002; d = 0.16 to 0.26). No significant differences between the conditions were observed for outcomes related to the Wingate and CMJ tests. CONCLUSION: This study provided novel evidence into the effectiveness of caffeine, paracetamol, and their combination on exercise performance. We found improvements in muscular endurance, strength, or power only when caffeine was consumed in isolation, or in combination with paracetamol. Isolated paracetamol consumption did not improve performance for any of the analyzed outcomes, thus calling into question its ergogenic potential.


Asunto(s)
Acetaminofén , Cafeína , Estudios Cruzados , Fuerza Muscular , Sustancias para Mejorar el Rendimiento , Resistencia Física , Humanos , Cafeína/administración & dosificación , Cafeína/farmacología , Acetaminofén/farmacología , Acetaminofén/administración & dosificación , Método Doble Ciego , Masculino , Fuerza Muscular/efectos de los fármacos , Resistencia Física/efectos de los fármacos , Resistencia Física/fisiología , Femenino , Adulto Joven , Sustancias para Mejorar el Rendimiento/administración & dosificación , Sustancias para Mejorar el Rendimiento/farmacología , Adulto , Entrenamiento de Fuerza , Músculo Esquelético/efectos de los fármacos , Músculo Esquelético/fisiología , Rendimiento Atlético/fisiología
5.
Nutrients ; 16(17)2024 Aug 26.
Artículo en Inglés | MEDLINE | ID: mdl-39275165

RESUMEN

This study analyzes the effects on body composition and variables related to metabolic syndrome of two coffees with different degree of roasting and phenolic content. Sixty participants with body mass index between 25 and 35 kg/m2 and a median age of 51.0 years (Interquartile range 46.3-56) were recruited. The study was a controlled, randomized, single-blind crossover trial consisting in drinking three cups/day of roasted coffee (RC) or lightly roasted coffee (LRC) during 12 weeks with 2-week wash-out stages before each coffee intervention. LRC contained ≈400 mg of hydroxycinnamic acids and ≈130 mg of caffeine per 200 mL/cup while RC contained ≈150 mg of hydroxycinnamic acids and ≈70 mg of caffeine per 200 mL/cup. Along the study, in each of the six visits, blood pressure, body composition by bioimpedance, anthropometric measurements, and blood biochemistry were analyzed. The mean differences and p values were calculated using a linear mixed model (JASP.v.0.18.0.3). A total of 38 participants completed the study. After the consumption of both coffees, fat mass and body fat percentage (LRC: -1.4%, p < 0.001; RC: -1.0%, p = 0.005) were reduced, whereas muscle mass and muscle mass percentage slightly increased (LRC: 0.8%, p < 0.001; RC: 0.7%, p = 0.002). The decrease in fat percentage was greater with LRC compared to RC (-0.8%; p = 0.029). There were no significant changes in metabolic syndrome variables or in body weight. In conclusion, LRC was slightly superior at inducing changes in body composition.


Asunto(s)
Composición Corporal , Café , Estudios Cruzados , Obesidad , Sobrepeso , Fenoles , Humanos , Café/química , Persona de Mediana Edad , Masculino , Composición Corporal/efectos de los fármacos , Femenino , Método Simple Ciego , Fenoles/análisis , Obesidad/dietoterapia , Sobrepeso/dietoterapia , Cafeína/administración & dosificación , Índice de Masa Corporal , Adulto , Ácidos Cumáricos/análisis , Síndrome Metabólico/dietoterapia
6.
Nutrients ; 16(16)2024 Aug 20.
Artículo en Inglés | MEDLINE | ID: mdl-39203905

RESUMEN

Caffeine's metabolism is determined by CYP1A2 genotypes: AC/CC (SLOW) and AA (FAST). This trial evaluated CYP1A2 genotypes' impact on exercise and cognitive effects in 36 resistance-trained females assessed under placebo (PL) and caffeine (6 mg/kg bw anhydrous caffeine-CAF) conditions, before ingestion and throughout the session. 23andMe® (San Francisco, CA, USA) determined genotypes using saliva. Data were analyzed using two-way RMANOVA and paired-samples t-tests (p < 0.05). A significant main effect for genotype existed for leg press repetitions to failure (RTF) for CAF (p = 0.038), with the FAST group performing more repetitions than the SLOW (p = 0.027). There was a significant condition x genotype interaction for the subjective outcome index score (p = 0.045), with significant differences for time (p < 0.01) and between genotype (p < 0.001). Follow-up analysis revealed a higher total score (p = 0.028) following CAF for the FAST group and a lower total score (p < 0.01) in the SLOW group. Dizziness was reported following CAF in the SLOW group (p = 0.014; Cohen's d = 0.725). Aside from leg press RTF, subjective outcome index score, and dizziness, the genotype groups experienced similar responses to resistance exercise performance and subjective mood states following caffeine ingestion.


Asunto(s)
Afecto , Cafeína , Citocromo P-450 CYP1A2 , Genotipo , Entrenamiento de Fuerza , Humanos , Cafeína/farmacología , Cafeína/administración & dosificación , Femenino , Citocromo P-450 CYP1A2/genética , Citocromo P-450 CYP1A2/metabolismo , Afecto/efectos de los fármacos , Adulto Joven , Adulto , Sustancias para Mejorar el Rendimiento/administración & dosificación , Sustancias para Mejorar el Rendimiento/farmacología , Método Doble Ciego
7.
Behav Brain Funct ; 20(1): 19, 2024 Aug 05.
Artículo en Inglés | MEDLINE | ID: mdl-39103929

RESUMEN

Caffeine is a widely used drug that broadly affects human cognition and brain function. Caffeine acts as an antagonist to the adenosine receptors in the brain. Previous anecdotal reports have also linked caffeine intake with changes in pupil diameter. By modifying the retinal irradiance, pupil diameter modulates all ocular light exposure relevant for visual (i.e., perception, detection and discrimination of visual stimuli) and non-visual (i.e., circadian) functions. To date, the extent of the influence of caffeine on pupillary outcomes, including pupil diameter, has not been examined in a systematic review. We implemented a systematic review laid out in a pre-registered protocol following PRISMA-P guidelines. We only included original research articles written in English reporting studies with human participants, in which caffeine was administered, and pupil diameter was measured using objective methods. Using broad search strategies, we consulted various databases (PsycINFO, Medline, Embase, Cochrane Library, bioRxiv and medRxiv) and used the Covidence platform to screen, review and extract data from studies. After importing studies identified through database search (n = 517 imported, n = 46 duplicates), we screened the title and abstracts (n = 471), finding 14 studies meeting our eligibility criteria. After full-text review, we excluded seven studies, leaving only a very modest number of included studies (n = 7). Extraction of information revealed that the existing literature on the effect of caffeine on pupil parameters is very heterogeneous, differing in pupil assessment methods, time of day of caffeine administration, dose, and protocol timing and design. The evidence available in the literature does not provide consistent results but studies rated as valid by quality assessment suggest a small effect of caffeine on pupil parameters. We summarize the numeric results as both differences in absolute pupil diameter and in terms of effect sizes. More studies are needed using modern pupil assessment methods, robust study design, and caffeine dose-response methodology.


Asunto(s)
Cafeína , Pupila , Humanos , Cafeína/farmacología , Cafeína/administración & dosificación , Pupila/efectos de los fármacos , Pupila/fisiología , Estimulantes del Sistema Nervioso Central/farmacología , Estimulantes del Sistema Nervioso Central/administración & dosificación
8.
Eur J Pharm Sci ; 201: 106875, 2024 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-39121922

RESUMEN

The goal of this research was to augment the deposition of caffeine loaded Transcutol® enriched cerosomes (TECs) gel for efficient topical treatment of cellulite utilizing the sonophoresis technique. Caffeine-loaded TECs were prepared using thin film hydration method applying 23 factorial design to study the impact of different factors, each with two levels on the entrapment efficiency (EE%), particle size (PS), polydispersity index (PDI), and zeta potential (ZP) of the formulated TECs. The studied factors were cetyl trimethyl ammonium bromide (CTAB) amount (mg) (X1), phosphatidylcholine (PC) amount (mg) (X2), and Transcutol® amount (mg) (X3). Design-Expert® software was utilized to determine the optimum TECs formulation. Afterward, the optimum TECs formulation was loaded into a gel and subjected to extra investigations. The optimum TECs formulation was (TEC5) which was prepared using 10 mg of CTAB, 150 mg of PC, and 10 mg of Transcutol®. TEC5 presented EE% of 87.44 ± 0.14 %, PS of 308.60 ± 13.38 nm, PDI of 0.455 ± 0.030, and ZP of 50.20 ± 1.55 mV. TEC5 had a fiber-like morphology, with elongated tubules of ceramide. Further, the optimum TECs formulation showed a high stability profile. Moreover, an in vivo dermatokinetic study showed superior deposition of caffeine from TEC5 gel coupled with the sonophoresis on rat skin compared to TEC5 gel and caffeine gel. Moreover, the histopathological study of TEC5 on rat skin confirmed the non-irritant nature of TEC 5 gel mediated by ultrasonic waves through the skin. Overall, the outcomes exposed the obvious superiority of sonophoresis delivered TECs-gel for topical delivery of caffeine for cellulite management.


Asunto(s)
Cafeína , Celulitis , Ratas Wistar , Cafeína/química , Cafeína/administración & dosificación , Animales , Celulitis/terapia , Masculino , Administración Cutánea , Ratas , Absorción Cutánea , Difusión , Liposomas , Tamaño de la Partícula , Piel/metabolismo , Administración Tópica , Liberación de Fármacos , Glicoles de Etileno
9.
Life Sci ; 354: 122971, 2024 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-39147313

RESUMEN

AIM: Maternal caffeine crosses the placenta and mammary barriers, reaching the baby and, because his/her caffeine metabolism is immature, our hypothesis is that even a low caffeine intake (250 mg/day), lower than the dose limit recommended by the World Health Organization, can promote caffeine overexposure in the offspring, leading to short- and long-term changes. MAIN METHODS: Pregnant Wistar rats received intragastric caffeine (CAF) (25 mg/Kg/day) or vehicle during the gestation and lactation periods. We evaluated morphometrical, metabolic, hormonal, and behavioral parameters of male and female offspring at different ages. KEY FINDINGS: Even a low caffeine intake promoted lower maternal body mass and adiposity, higher plasma cholesterol and lower plasma T3, without changes in plasma corticosterone. Female CAF offspring exhibited lower birth weight, body mass gain and food intake throughout life, and hyperinsulinemia at weaning, while male CAF offspring showed reduced food intake and lower plasma T3 at weaning. At puberty and adulthood, male CAF showed higher preference for palatable food, aversion to caffeine intake and higher locomotor activity, while female CAF only showed lower preference for high fat diet (HFD) and lower anxiety-like behavior. At adulthood, both male and female offspring showed higher plasma T3. Male CAF showed hypertestosteronemia, while female CAF showed hypoinsulinemia without effect on glucose tolerance. SIGNIFICANCE: A low caffeine intake during the perinatal period affects rat's offspring development, promoting sex-dependent hormonal and behavior changes. Current data suggest the need to review caffeine recommendations during the perinatal period.


Asunto(s)
Conducta Animal , Cafeína , Efectos Tardíos de la Exposición Prenatal , Ratas Wistar , Animales , Femenino , Cafeína/administración & dosificación , Masculino , Embarazo , Ratas , Conducta Animal/efectos de los fármacos , Lactancia , Ingestión de Alimentos/efectos de los fármacos , Factores Sexuales
10.
BMC Health Serv Res ; 24(1): 909, 2024 Aug 07.
Artículo en Inglés | MEDLINE | ID: mdl-39113051

RESUMEN

BACKGROUND: The objective of this research was to examine how caffeine use disorder among physicians across different specialties relates to both sleep quality and professional burnout. METHODS: This research represents a single-center, prospective, cross-sectional study involving 240 physicians meeting inclusion criteria and working within a training and research hospital. Participants were enrolled in the study after obtaining informed consent. A web-based survey methodology was employed, administering a participant information form crafted following an exhaustive literature review, alongside assessments utilizing the Caffeine Use Disorder Questionnaire, the Pittsburgh Sleep Quality Index, and the Maslach Burnout Inventory. A significance level of p < 0.05 was considered statistically significant. RESULTS: In our study, participants had a median age of 30.0 years, and 60% reported poor sleep quality. A positive and statistically significant relationship (rho=0.148, p = 0.022) was found between the Caffeine Use Disorder Questionnaire and Pittsburgh Sleep Quality Index scores. In the generalized linear model analysis, setting the Caffeine Use Disorder Questionnaire score as the dependent variable, statistically significant contributions were observed for gender (women), daily total caffeine intake, and Maslach-depersonalization score variables (p = 0.012, p < 0.001, 0.035, respectively). CONCLUSIONS: Higher levels of caffeine use disorder have been observed among women, smokers, and individuals with increased caffeine intake. Notably, an increase in professional depersonalization is associated with a rise in caffeine use disorder. Studying physicians' professional depersonalization could aid in addressing caffeine use disorders. Additionally, exploring the caffeine consumption patterns of healthcare professionals displaying depersonalization towards patients' needs is also worthwhile.


Asunto(s)
Agotamiento Profesional , Cafeína , Médicos , Humanos , Estudios Transversales , Femenino , Masculino , Adulto , Cafeína/administración & dosificación , Estudios Prospectivos , Encuestas y Cuestionarios , Médicos/psicología , Médicos/estadística & datos numéricos , Agotamiento Profesional/epidemiología , Calidad del Sueño , Persona de Mediana Edad
12.
PLoS One ; 19(8): e0309287, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-39213264

RESUMEN

OBJECTIVE: Lifestyle habits after middle age significantly impact the maintenance of cognitive function in older adults. Nutritional intake is closely related to lifestyle habits; therefore, nutrition is a pivotal factor in the prevention of dementia in the preclinical stages. Matcha green tea powder (matcha), which contains epigallocatechin gallate, theanine, and caffeine, has beneficial effects on cognitive function and mood. We conducted a randomized, double-blind, placebo-controlled clinical study over 12 months to examine the effect of matcha on cognitive function and sleep quality. METHODS: Ninety-nine participants, including 64 with subjective cognitive decline and 35 with mild cognitive impairment were randomized, with 49 receiving 2 g of matcha and 50 receiving a placebo daily. Participants were stratified based on two factors: age at baseline and APOE genotype. Changes in cognitive function and sleep quality were analyzed using a mixed-effects model. RESULTS: Matcha consumption led to significant improvements in social acuity score (difference; -1.39, 95% confidence interval; -2.78, 0.002) (P = 0.028) as evaluated by the perception of facial emotions in cognitive function. The primary outcomes, that is, Montreal Cognitive Assessment and Alzheimer's Disease Cooperative Study Activity of Daily Living scores, showed no significant changes with matcha intervention. Meanwhile, Pittsburgh Sleep Quality Index scores indicated a trend toward improvement with a difference of 0.86 (95% confidence interval; -0.002, 1.71) (P = 0.088) between the groups in changes from baseline to 12 months. CONCLUSIONS: The present study suggests regular consumption of matcha could improve emotional perception and sleep quality in older adults with mild cognitive decline. Given the widespread availability and cultural acceptance of matcha green tea, incorporating it into the daily routine may offer a simple yet effective strategy for cognitive enhancement and dementia prevention.


Asunto(s)
Catequina , Cognición , Disfunción Cognitiva , Calidad del Sueño , , Humanos , Femenino , Masculino , Anciano , Disfunción Cognitiva/prevención & control , Cognición/efectos de los fármacos , Método Doble Ciego , Catequina/análogos & derivados , Catequina/administración & dosificación , Catequina/uso terapéutico , Cafeína/administración & dosificación , Cafeína/farmacología , Glutamatos/uso terapéutico , Glutamatos/administración & dosificación , Persona de Mediana Edad , Anciano de 80 o más Años
13.
Conscious Cogn ; 124: 103729, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-39098270

RESUMEN

Participants completed two sessions of an auditory attention task and intermittently responded to thought probes asking about their level of mind-wandering. After the first session one group received 200 mg of caffeinated chewing gum (n = 61) and another group received regular (placebo) chewing gum (n = 66). The gum was chewed for 20-minutes and then disposed of before beginning the second session. Participants who received caffeine showed a performance benefit as well as reported being more on task and fewer instances of spontaneous mind-wandering compared to those in the placebo group. Participants who received caffeine also reported greater positive affect and arousal, as well as less feelings of boredom, sleepiness, and mental effort required to stay on task compared to those who received placebo. These results suggest that caffeine may benefit attentional engagement as well as performance during a sustained attention task.


Asunto(s)
Nivel de Alerta , Atención , Cafeína , Estimulantes del Sistema Nervioso Central , Humanos , Cafeína/farmacología , Cafeína/administración & dosificación , Atención/efectos de los fármacos , Atención/fisiología , Masculino , Femenino , Adulto Joven , Estimulantes del Sistema Nervioso Central/farmacología , Estimulantes del Sistema Nervioso Central/administración & dosificación , Adulto , Nivel de Alerta/efectos de los fármacos , Nivel de Alerta/fisiología , Percepción Auditiva/fisiología , Percepción Auditiva/efectos de los fármacos , Afecto/efectos de los fármacos , Afecto/fisiología , Goma de Mascar , Adolescente , Tedio
14.
Sci Rep ; 14(1): 19082, 2024 08 17.
Artículo en Inglés | MEDLINE | ID: mdl-39154109

RESUMEN

Therapeutic hypothermia is the standard treatment for hypoxic-ischemic encephalopathy (HIE), but despite its widespread use, the rates of mortality and neurodevelopmental impairment for moderate to severe HIE remain around 30%. Methylxanthines, such as caffeine and aminophylline, have potential neuroprotective effects in the setting of hypoxic-ischemic injury. However, data on the safety and efficacy of methylxanthines in the setting of therapeutic hypothermia for HIE are limited. This retrospective multicenter study examined in-hospital outcomes in 52 infants with HIE receiving methylxanthines and therapeutic hypothermia. The frequency of mortality and in-hospital morbidities were similar to those of infants enrolled in clinical trials undergoing therapeutic hypothermia without adjunctive therapies. Clinical trials of methylxanthines for neuroprotection in HIE are needed to determine safety and efficacy and should explore optimal dosing and timing of methylxanthine administration.


Asunto(s)
Hipotermia Inducida , Hipoxia-Isquemia Encefálica , Fármacos Neuroprotectores , Xantinas , Humanos , Hipoxia-Isquemia Encefálica/tratamiento farmacológico , Estudios Retrospectivos , Masculino , Femenino , Xantinas/uso terapéutico , Recién Nacido , Fármacos Neuroprotectores/uso terapéutico , Hipotermia Inducida/métodos , Cafeína/uso terapéutico , Cafeína/administración & dosificación , Lactante , Resultado del Tratamiento , Aminofilina/uso terapéutico , Aminofilina/administración & dosificación
15.
Eur J Pharm Biopharm ; 203: 114434, 2024 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-39098618

RESUMEN

Modifications to the small intestine and liver are known to occur during the symptomatic disease period of amyotrophic lateral sclerosis (ALS), a member of the motor neuron disease (MND) family of neurodegenerative disorders. How these modifications impact on oral absorption and pharmacokinetics of drugs remains unknown. In this study, model drugs representing different mechanisms of intestinal transport (caffeine for passive diffusion, digoxin for P-glycoprotein efflux, and sulfasalazine for breast cancer resistance protein efflux) were administered via oral gavage to postnatal day 114-120 male and female SOD1G93A mice (model of familial ALS) and wild-type (WT) littermates. Samples of blood, brain and spinal cord were taken at either 15, 30, 60 or 180 min after administration. In addition, the in vivo gastric emptying of 70 kDa fluorescein isothiocyanate-dextran (FITC-dextran) and the ex vivo intestinal permeability of caffeine were assessed. The area under the plasma concentration-time curves (AUCplasma) of digoxin and sulfasalazine were not significantly different between SOD1G93A and WT mice for both sexes. However, the AUCplasma of caffeine was significantly lower (female: 0.79-fold, male: 0.76-fold) in SOD1G93A compared to WT mice, which was associated with lower AUCbrain (female: 0.76-fold, male: 0.80-fold) and AUCspinal cord (female: 0.81-fold, male: 0.82-fold). The AUCstomach of caffeine was significantly higher (female: 1.5-fold, male: 1.9-fold) in SOD1G93A compared to WT mice, suggesting reduced gastric emptying in SOD1G93A mice. In addition, there was a significant reduction in gastric emptying of FITC-dextran (0.66-fold) and ex vivo intestinal permeability of caffeine (0.52-fold) in male SOD1G93A compared to WT mice. Reduced systemic and brain/spinal cord exposure of caffeine in SOD1G93A mice may therefore result from alterations to gastric emptying and small intestinal permeability. Specific dosing requirements may therefore be required for certain medicines in ALS to ensure that they remain in a safe and effective concentration range.


Asunto(s)
Esclerosis Amiotrófica Lateral , Encéfalo , Cafeína , Modelos Animales de Enfermedad , Ratones Transgénicos , Médula Espinal , Animales , Cafeína/administración & dosificación , Cafeína/farmacocinética , Esclerosis Amiotrófica Lateral/tratamiento farmacológico , Esclerosis Amiotrófica Lateral/metabolismo , Médula Espinal/metabolismo , Médula Espinal/efectos de los fármacos , Masculino , Femenino , Ratones , Administración Oral , Encéfalo/metabolismo , Encéfalo/efectos de los fármacos , Superóxido Dismutasa-1/genética , Superóxido Dismutasa-1/metabolismo , Digoxina/farmacocinética , Digoxina/administración & dosificación , Sulfasalazina/farmacocinética , Sulfasalazina/administración & dosificación , Absorción Intestinal/efectos de los fármacos , Absorción Intestinal/fisiología
16.
Sleep Med ; 122: 71-83, 2024 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-39137663

RESUMEN

BACKGROUND: Studies have found that the use of clinically approved caffeine and modafinil can alleviate cognitive impairment due to sleep deprivation (SD) to some extent. However, the neural mechanisms by which these two cognitive enhancers work to counteract the effects of SD on cognitive impairment remain unclear. METHODS: A double-blind within-subjects experiment using resting-state functional magnetic resonance imaging (rs-fMRI) was designed. Participants underwent three 36-h SD trials, each of which involved taking 200 mg of caffeine, modafinil, or placebo at the 28th and 32 nd h of SD. Sixteen subregions of the thalamus were selected as the regions of interest and changes in functional connectivity (FC) between the thalamus and the other brain regions were explored after the participants took caffeine or modafinil. RESULTS: The subjective sleepiness of the participants increased with the duration of SD. compared with placebo, modafinil and caffeine had insignificant effects on wakefulness or sleepiness. However, in terms of neural FC, we found varying degrees of attenuation or enhancement of the FC between the thalamus and other regions. Taking caffeine during SD weakened the FC between the right rostral temporal thalamus (rTtha) subregion and the left lingual gyrus compared with placebo. Caffeine enhanced the FC between three subregions of the thalamus, namely the left sensory thalamus, the left rTtha, and the right lateral pre-frontal thalamus, and the right inferior temporal, left orbitofrontal, and right superior occipital gyris. Modafinil weakened the FC between the right posterior parietal thalamus and left middle temporal gyrus, and enhanced the FC between the left medial pre-frontal thalamus, left rTtha, and right occipital thalamus and left middle frontal gyrus. CONCLUSIONS: After 36 h of total SD, modafinil and caffeine administration enhanced or attenuated the time-domain correlations between various subregions of the thalamus and brain regions of the frontal and temporal lobes in healthy adults, compared with placebo. These results provide valuable evidence for further unraveling the neuropharmacological mechanisms of caffeine and modafinil, as well as important insights for exploring effective pharmacological intervention strategies against SD.


Asunto(s)
Cafeína , Imagen por Resonancia Magnética , Modafinilo , Privación de Sueño , Tálamo , Humanos , Cafeína/farmacología , Cafeína/administración & dosificación , Cafeína/uso terapéutico , Modafinilo/farmacología , Modafinilo/uso terapéutico , Privación de Sueño/tratamiento farmacológico , Privación de Sueño/complicaciones , Privación de Sueño/fisiopatología , Método Doble Ciego , Tálamo/efectos de los fármacos , Tálamo/diagnóstico por imagen , Masculino , Proyectos Piloto , Adulto , Femenino , Estimulantes del Sistema Nervioso Central/farmacología , Estimulantes del Sistema Nervioso Central/uso terapéutico , Promotores de la Vigilia/farmacología , Promotores de la Vigilia/uso terapéutico , Adulto Joven
18.
Nutrients ; 16(15)2024 Jul 26.
Artículo en Inglés | MEDLINE | ID: mdl-39125317

RESUMEN

There is evidence that both intra-serial variable resistance (I-sVR), as pre-activation within the post-activation performance enhancement cycle (PAPE), and creatine and caffeine supplementation increase athletic performance in isolation. However, the effect of the three conditioning factors on 30 m repeated sprint ability (RSA) performance in young soccer players is unknown. This study determined the summative and isolation effect of ergogenic aids and pre-activation in half-back squats (HBSs) with I-sVR on performance in an RSA test in young soccer players. Twenty-eight young soccer players were randomly assigned to either EG1 (n = 7, creatine + caffeine + I-sVR), EG2 (n = 7, creatine + placebo2 + I-sVR), EG3 (n = 7, placebo1 + caffeine + I-sVR), or EG4 (n = 7, placebo1 + placebo2 + I-sVR), using a factorial, four-group-matched, double-blind, placebo-controlled design. Creatine supplementation included 0.3 g/kg/day for 14 days, caffeine supplementation included 0.3 mg/kg per day, and pre-activation in HBS with I-sVR (1 × 5 at 30% 1RM [1.0-1.1 m/s] + 1 × 4 at 60% 1RM [0.6-0.7 m/s]). The RSA test and HBS outcomes were evaluated. Three-way ANOVA showed non-significant differences for the RSA test and HBS outcomes (p > 0.05). At the end of this study, it was found that the three ergogenic aids, together, do not generate a summative effect on the physical performance of young soccer players. However, it is important to analyze individual responses to these specific protocols.


Asunto(s)
Rendimiento Atlético , Cafeína , Creatina , Suplementos Dietéticos , Carrera , Fútbol , Humanos , Fútbol/fisiología , Cafeína/administración & dosificación , Cafeína/farmacología , Rendimiento Atlético/fisiología , Creatina/administración & dosificación , Creatina/farmacología , Adolescente , Masculino , Método Doble Ciego , Carrera/fisiología , Entrenamiento de Fuerza , Sustancias para Mejorar el Rendimiento/administración & dosificación , Sustancias para Mejorar el Rendimiento/farmacología , Atletas
19.
BMJ Open Respir Res ; 11(1)2024 Aug 28.
Artículo en Inglés | MEDLINE | ID: mdl-39209350

RESUMEN

OBJECTIVE: The guidelines recommend early caffeine administration for preterm infants requiring non-invasive mechanical ventilation since earlier treatment is associated with better outcomes. The objective was to evaluate the impact of early caffeine therapy (within 24 hours after birth) on respiratory outcomes in very preterm infants who were initially receiving invasive mechanical ventilation. METHODS: This was an observation cohort study from 1 January 2018 to 31 December 2022 based on a database that was prospectively collected and maintained. Infants who initially received invasive mechanical ventilation were divided into two groups based on the timing of caffeine initiation: within the first 24 hours after birth (early) and within 48 hours of birth or later (late). Generalised linear mixed models with a random effect model for the centre were used to assess the impact of different caffeine initiation times on neonatal outcomes. RESULTS: Among the cohort of 9880 infants born at <32 weeks gestation, 2381 were eligible for this study (early initiation: 1758 (73.8%) and late initiation: 623 (26.2%)). For infants born at more than 28 weeks of gestation, the adjusted generalised linear mixed model showed that the duration of invasive mechanical ventilation was 1.34 (95% CI -2.40 to -0.27) days shorter and the incidence of moderate-to-severe bronchopulmonary dysplasia (BPD) was lower (adjusted OR 0.63; 95% CI 0.41 to 0.96) in the early caffeine group compared with the late caffeine group. CONCLUSION: In very preterm infants who initially receive invasive mechanical ventilation, early administration of caffeine within 24 hours after birth can shorten the duration of invasive mechanical ventilation, reduce the incidence of moderate-to-severe BPD and improve respiratory outcomes. The very early initiation of caffeine treatment does not appear to be associated with any adverse outcomes. TRIAL REGISTRATION NUMBER: ChiCTR1900025234.


Asunto(s)
Cafeína , Respiración Artificial , Humanos , Cafeína/administración & dosificación , Recién Nacido , Femenino , Masculino , Recien Nacido Prematuro , Edad Gestacional , Displasia Broncopulmonar/prevención & control , Displasia Broncopulmonar/epidemiología , Factores de Tiempo , Estudios de Cohortes , Resultado del Tratamiento , Estimulantes del Sistema Nervioso Central/administración & dosificación , Síndrome de Dificultad Respiratoria del Recién Nacido/terapia , Estudios Prospectivos , Recien Nacido Extremadamente Prematuro
20.
Prog Brain Res ; 288: 133-166, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-39168555

RESUMEN

This chapter thoroughly examines coffee's impact on cognitive function. It synthesizes research findings involving animals and humans, investigating coffee's influence on various memory and cognitive aspects, including short-term/working memory, long-term memory, attention, vigilance, executive functions, and processing speed. The chapter also discusses moderating factors, such as dose-response relationships, individual differences, age, and habitual consumption patterns, that influence the cognitive effects of coffee. Additionally, it addresses the potential risks and adverse effects associated with coffee intake, memory, and cognitive function, including stress and anxiety, sleep disturbances, cardiovascular effects, and addiction. Studies suggest moderate coffee intake improves attention, processing speed, decision-making, and certain executive functions. However, the effects vary depending on factors like dosage, individual traits, age, and sleep habits. Despite potential benefits, coffee consumption may lead to adverse effects such as anxiety, sleep issues, cardiovascular concerns, and dependency. Future research should address methodological concerns, incorporate neuroimaging methods, explore interactions with other substances, and investigate long-term effects and therapeutic uses. Understanding coffee's neuroscience can shed light on its role in daily life and health.


Asunto(s)
Café , Cognición , Humanos , Cognición/efectos de los fármacos , Cognición/fisiología , Animales , Memoria/fisiología , Memoria/efectos de los fármacos , Atención/fisiología , Atención/efectos de los fármacos , Cafeína/farmacología , Cafeína/administración & dosificación , Cafeína/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA